文献速递胸部肿瘤

非小细胞肺癌中程序性死亡受体1的表达及其临床病理特征与预后同表皮生长因子受体基因突变的关系

[The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2017-01-01

该研究采用免疫组化SP法检测88例非小细胞肺癌(NSCLC)组织及癌旁组织中程序性死亡受体1(PD-1)的表达,并用等位基因特异性扩增测序法检测EGFR突变。结果显示PD-1在NSCLC组织中阳性表达率为63.6%(56/88),高于癌旁正常组织的21.6%(19/88,P<0.05);PD-1表达与吸烟、淋巴结转移及EGFR突变类型有关,PD-1阳性患者中位无进展生存时间较阴性患者短。

要点

  • PD-1在NSCLC组织中阳性表达率为63.6%(56/88),高于癌旁正常组织的21.6%(19/88,P<0.05)。
  • PD-1表达与吸烟、淋巴结转移及EGFR基因突变类型有关(均P<0.05)。
  • 全组PD-1阳性 vs 阴性中位无进展生存时间为7.03 vs 18.66个月(P=0.007)。

核心结论

  • PD-1在EGFR基因突变型和野生型NSCLC中均有表达,不同EGFR突变类型中的表达存在差异。
  • PD-1在NSCLC组织中的表达与患者预后有关,PD-1阳性表达患者的预后较差。

研究设计与样本

  • 采用免疫组化SP法检测88例NSCLC组织及癌旁组织中PD-1蛋白的表达。
  • 采用等位基因特异性扩增测序法(PCR-ARMS)检测NSCLC组织EGFR的突变情况和突变类型。
  • 分析PD-1表达与NSCLC临床病理特征和预后的关系。

主要发现

  • PD-1在NSCLC组织中的阳性表达率为63.6%(56/88),高于癌旁正常组织的21.6%(19/88,P<0.05)。
  • EGFR基因突变型43例(48.9%),其中PD-1阳性表达30例(69.8%);EGFR基因野生型45例,其中PD-1阳性表达26例(57.8%)。
  • 43例EGFR基因突变患者中,19Del突变24例,其中PD-1阳性表达20例(83.3%);21L858突变19例,其中PD-1阳性表达10例(52.6%)。
  • PD-1在NSCLC组织中的表达与患者是否吸烟、淋巴结转移情况和EGFR基因突变类型有关(均P<0.05)。
  • 全组PD-1阳性 vs 阴性表达患者的中位无进展生存时间分别为7.03 vs 18.66个月(P=0.007)。

关键数值与推荐

  • EGFR基因野生型患者中,PD-1阳性 vs 阴性表达的中位无进展生存时间分别为25.21 vs 38.24个月(P=0.024)。
  • EGFR基因突变型患者中,PD-1阳性 vs 阴性表达的中位无进展生存时间分别为21.23 vs 31.44个月(P=0.128)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the relationships between the expression of programmed death 1 (PD-1) and the epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC). The study also attempted to investigate the clinicopathological features and prognosis in NSCLC patients. Methods: The expression of PD-1 protein in 88 cases of NSCLC tumor tissues and adjacent tissues was detected by immunohistochemistry. The mutations of EGFR in NSCLC were detected by Polymerase Chain Reaction-Amplification Refractory Mutation System(PCR-ARMS) method. The expression of PD-1 and patients' clinical characteristics and prognosis were analyzed. Results: PD-1 was positive in 63.6%(56/88) NSCLC tumor tissues, which was significantly higher than that in adjacent normal tissues (21.6%, 19/88) (P<0.05). EGFR gene mutations were found in 43 cases (48.9%), in which 30 cases (69.8%)were PD-1 positive expression. 45 cases had the wild types of EGFR gene, in which 26 cases (57.8%) were PD-1 positive. There were 24 cases of 19Del EGFR mutations, including 20 cases (83.3%) of PD-1 positive expression. 19 patients had 21L858 EGFR mutations, including 10 cases (52.6%) of PD-1 positive expression. The expression of PD-1 in NSCLC was related to patients' smoking status, lymph node metastasis and EGFR gene mutations (P<0.05). The median progression-free survival time of patients with PD-1 positive and negative expression was 7.03 and 18.66 months, respectively (P=0.007). In patients with wild-type EGFR gene, the median progression-free survival time of PD-1 positive and negative expression was 25.21 and 38.24 months, respectively. The difference was statistically significant (P=0.024). The median progression-free survival time in 43 cases of EGFR mutant patients with PD-1 positive and negative expression was 21.23 and 31.44 months. The difference was not statistically significant (P=0.128). Conclusions: PD-1 expresses in both EGFR mutant and wild-type NSCLC, and its expression levelis different with various EGFR mutations. The expression of PD-1 in NSCLC is related to the prognosis of patients, and the prognosis of patients with positive PD-1 expression was poor. 目的: 探讨程序性死亡受体1(PD-1)在非小细胞肺癌(NSCLC)组织中的表达与表皮生长因子受体(EGFR)基因突变和其他临床病理特征之间的关系,以及对患者预后的影响。 方法: 采用免疫组化SP法检测88例NSCLC组织及癌旁组织中PD-1的表达,采用等位基因特异性扩增测序法检测NSCLC组织EGFR的突变情况和突变类型,并分析其与NSCLC临床病理特征和预后的关系。 结果: PD-1在NSCLC组织中的阳性表达率为63.6%(56/88),明显高于癌旁正常组织(21.6%,19/88;P<0.05)。EGFR基因突变型43例,突变率为48.9%,其中PD-1阳性表达30例(69.8%);EGFR基因野生型45例,其中PD-1阳性表达26例(57.8%)。43例EGFR基因突变患者中,19Del突变24例,其中PD-1阳性表达20例(83.3%);21L858突变19例,其中PD-1阳性表达10例(52.6%)。PD-1在NSCLC组织中的表达与患者是否吸烟、淋巴结转移情况和EGFR基因突变类型有关(均P<0.05)。全组PD-1阳性和阴性表达患者的中位无进展生存时间分别为7.03和18.66个月,差异有统计学意义(P=0.007)。在EGFR基因野生型患者中,PD-1阳性和阴性表达患者的中位无进展生存时间分别为25.21和38.24个月,差异有统计学意义(P=0.024)。在EGFR基因突变型患者中,PD-1阳性和阴性表达患者的中位无进展生存时间分别为21.23和31.44个月,差异无统计学意义(P=0.128)。 结论: PD-1在EGFR基因突变型和野生型NSCLC中均有表达,不同基因突变类型中的表达存在差异。PD-1在NSCLC组织中的表达与患者的预后有关,阳性表达患者的预后较差。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yin H, Liao CG, Wang YQ, et al. [The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28635230. doi:10.3760/cma.j.issn.0253-3766.2017.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。